Decreasing Levels of HBsAg Predict HBsAg Seroclearance in Patients With Inactive Chronic Hepatitis B Virus Infection

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 3, 2012, Pages 297-302

  Chen, Yi Cheng ^a   Jeng, Wen Juei ^a   Chu, Chia Ming ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Alanine Aminotransferase; HBeAg Negative Carrier; Negative Predictive Value; Positive Predictive Value; Receiver Operating Characteristic Curve Analysis

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGEN BLOOD LEVEL; HUMAN; MALE; PREDICTIVE VALUE; PROGNOSIS; VIRAL CLEARANCE; VIRUS SEROCLEARANCE;

ADULT; ALANINE TRANSAMINASE; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SERUM; TIME FACTORS;

EID: 84857194778     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.08.029     Document Type: Article

References (18)

1. Chen Y.C., Sheen I.S., Chu C.M., et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084-1089.
2. Arase Y., Ikeda K., Suzuki F., et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006, 119:e9-e16.
3. Chu C.M., Liaw Y.F. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010, 15:133-143.
4. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
5. Liaw Y.F., Sheen I.S., Chen T.J., et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13:627-631.
6. McMahon B.J., Holck P., Bulkow L., et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759-768.
7. Yuen M.F., Wong D.K., Sablon E., et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004, 39:1694-1701.
8. Nguyen T., Thompson A.J., Bowden S., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010, 52:508-513.
9. Jaroszewicz J., Calle Serrano B., Wursthorn K., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010, 52:514-522.
10. Chan H.L., Wong V.W., Wong G.L., et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010, 52:1232-1241.
11. Brunetto M.R., Oliveri F., Colombatto P., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139:483-490.
12. Wiegand J., Wedemeyer H., Finger A., et al. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir Ther 2008, 13:547-554.
13. Chen Y.C., Chu C.M., Liaw Y.F. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010, 51:435-444.
14. Chen Y.C., Chu C.M., Liaw Y.F., et al. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J Viral Hepat 2012, 19:138-146.
15. Wursthorn K., Jaroszewicz J., Zacher B.J., et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011, 50:292-296.
16. Martinot-Peignoux M., Lada O., Cardoso A.-C., et al. Quantitative HBsAg: a new specific marker for the diagnosis of HBsAg inactive carriage [abstract 1397]. Hepatology 2010, 52:992A.
17. Wursthorn K., Jung M., Riva A., et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010, 52:1611-1620.
18. Liu J., Yang H.I., Lee M.H., et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010, 139:474-482.